 | |
| Clinical data | |
|---|---|
| Other names | ψ-2C-O-35; 4-Difluoromethoxy-2,6-dimethoxyphenethylamine |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | ~18 hours[1] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C11H15F2NO3 |
| Molar mass | 247.242 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ψ-2C-DFMO, also known asψ-2C-O-35 or as4-difluoromethoxy-2,6-dimethoxyphenethylamine, is apsychedelic drug of thephenethylamine andψ-phenethylamine families.[2][1] It is the phenethylamine (α-demethyl)analogue ofψ-DODFMO and is also structurally related to other psychedelics likedifluoromescaline (DFM) and2C-T-35 (2C-T-DFM).[2][1] The drug has been found to be active at a dose of 17 mgorally, with moderately intense effects and a relatively longduration of around 18 hours.[2][1] Ψ-2C-DFMO was first described in thescientific literature byDaniel Trachsel in 2012.[2][1]
The introduction of two fluorine atoms into the 4-MeO group of Ψ-2C-O (61) seems to change biological activity distinctly and leads to a fairly active and long acting compound (Ψ-2C-DFMO, 68. A single experiment with 17 mg was stated to be only moderately intense although a relatively long duration around 18 h was observed. Its α-methyl analog Ψ-DODFMO (69) has been shown to be moderately active in a single experiment with 2x5 mg, which had a long duration of action (around 20 h) as well. [...] Up to now only very little biological data can be found for the derivatives of the 2,4,6-series. Compounds 62–69 may further help understanding the structure-activity relationships of this class. At least two novel derivatives have been assayed. A modification of the human inactive Ψ-2C-O (61, >300 mg) to the 4-difluoromethoxy analog Ψ-2C-DFMO (68, 17 mg) could greatly change the pharmacological properties in humans leading to a fairly potent derivative. The derivative Ψ-DODFMO (69) showed some effects at a dose of 2x5 mg. Although too little data are available so far, this suggests that similarly to the 3,4,5-series, from the presence of an α-methyl group in the 2,4,6-series only a modest difference in human dose may result.
 | Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it. |